Lawrence Kenyon
Direttore Finanziario/CFO presso OUTLOOK THERAPEUTICS, INC.
Patrimonio netto: 6 688 $ in data 31/05/2024
Posizioni attive di Lawrence Kenyon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 15/09/2015 | - |
| Direttore/Membro del Consiglio | 02/08/2018 | - | |
| Direttore Finanziario/CFO | 18/06/2018 | - | |
| Contatto Relazioni con gli Investitori | 15/09/2015 | - | |
| Segretario Aziendale | - | - | |
| Treasurer | - | - | |
| Amministratore Delegato | 18/06/2018 | 07/07/2021 | |
| Presidente | 02/08/2018 | 07/07/2021 |
Storia della carriera di Lawrence Kenyon
Precedenti posizioni note di Lawrence Kenyon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ARNO THERAPEUTICS, INC. | Direttore operativo | 18/07/2014 | 01/09/2015 |
| Direttore Finanziario/CFO | 24/02/2014 | 01/09/2015 | |
| Contatto Relazioni con gli Investitori | 24/02/2014 | 01/09/2015 | |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Amministratore Delegato | 23/12/2011 | 31/03/2013 |
| Direttore Finanziario/CFO | 23/12/2011 | 18/02/2013 | |
| Presidente | 23/12/2011 | 31/03/2013 | |
| Segretario Aziendale | 23/12/2011 | 31/03/2013 | |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Direttore Finanziario/CFO | 01/12/2008 | 01/07/2010 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Direttore Finanziario/CFO | 12/12/2008 | 04/06/2010 |
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Direttore/Membro del Consiglio | 01/02/2009 | 01/04/2009 |
| Direttore operativo | - | - | |
| Direttore Finanziario/CFO | 16/01/2007 | 01/02/2009 | |
| Presidente | - | - | |
| Segretario Aziendale | 16/01/2007 | 01/02/2009 | |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Direttore Finanziario/CFO | 01/09/2000 | 01/08/2006 |
| Segretario Aziendale | 01/09/2000 | 01/08/2006 |
Formazione di Lawrence Kenyon
| University of Wisconsin | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
Posizioni
| Director of Finance/CFO | 7 |
| Corporate Secretary | 4 |
| President | 3 |
Settori
| Health Technology | 7 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ARNO THERAPEUTICS, INC. | Health Technology |
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Endo Generics Holdings, Inc. develops, manufactures, and markets generic pharmaceutical products. It also offers dosage, branded, and generic sterile injectable products. The company was founded in 1978 and is headquartered in New York, NY. | Health Technology |
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Health Technology |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Health Technology |
- Borsa valori
- Insiders
- Lawrence Kenyon
- Esperienza
